Autologous Adipose-Derived Mesenchymal Stem Cells Embedded in Platelet-Rich Fibrin in Diabetic Foot Ulcers

Khalil, Charbel; Chaker, Diana; Salameh, Rawad; Germanos, Yvonne-Elise; Kayem, Elie El; Nader, Fady; Habbouche, J.; Chemaly, Rodrigue; Azar, Albert; Ibrahim, Ahmad

doi:10.4236/ojrm.2021.102002

Cited by 3 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Khalil et al reported that patients receiving AMSCs plus PRF had efficient wound healing compared to the patients receiving PRF alone. Their results were consistent with other studies proposing that MSCs secrete high levels of VEGF and HGF, and maintain a higher ratio of transforming growth factor (TGF)-β3 to TGF-β1; this contributes to cell migration, proliferation, improvement of vascular angiogenesis, and matrix deposition [ 106 ]. They also promote wound reepithelization, modified collagen deposition, and reduce scar formation [ 106 , 107 ].…”

Section: Stem Cell Therapysupporting

confidence: 91%

“…Furthermore, Khalil et al assessed the effectiveness of AMSCs embedded in autologous platelet-rich fibrin (PRF) on chronic DFU healing by comparing it to the treatment with PRF alone. They used this protocol as it has been assumed to be a cost-effective therapeutic approach, and better and faster than conventional chronic wound treatments [ 106 ]. Khalil et al reported that patients receiving AMSCs plus PRF had efficient wound healing compared to the patients receiving PRF alone.…”

Section: Stem Cell Therapymentioning

confidence: 99%

See 1 more Smart Citation

Stem Cell-Based Therapy: A Promising Treatment for Diabetic Foot Ulcer

et al. 2022

View full text Add to dashboard Cite

Diabetic foot ulcer (DFU) is a severe complication of diabetes and a challenging medical condition. Conventional treatments for DFU have not been effective enough to reduce the amputation rates, which urges the need for additional treatment. Stem cell-based therapy for DFU has been investigated over the past years. Its therapeutic effect is through promoting angiogenesis, secreting paracrine factors, stimulating vascular differentiation, suppressing inflammation, improving collagen deposition, and immunomodulation. It is controversial which type and origin of stem cells, and which administration route would be the most optimal for therapy. We reviewed the different types and origins of stem cells and routes of administration used for the treatment of DFU in clinical and preclinical studies. Diabetes leads to the impairment of the stem cells in the diseased patients, which makes it less ideal to use autologous stem cells, and requires looking for a matching donor. Moreover, angioplasty could be complementary to stem cell therapy, and scaffolds have a positive impact on the healing process of DFU by stem cell-based therapy. In short, stem cell-based therapy is promising in the field of regenerative medicine, but more studies are still needed to determine the ideal type of stem cells required in therapy, their safety, proper dosing, and optimal administration route.

show abstract

Section: Stem Cell Therapysupporting

confidence: 91%

Section: Stem Cell Therapymentioning

confidence: 99%

Stem Cell-Based Therapy: A Promising Treatment for Diabetic Foot Ulcer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…They followed this regimen since it is thought to be a more effective and efficient healing method than standard persistent wound care. 112 According to Khalil et al, 112 doing so does not give rise to any ethical concerns and the human placenta is less immunogenic than BM. Finally, a greater quantity of stem cells may be separated from the placenta than from BM.…”

Section: Adipose-derived Msc Therapy In Dfumentioning

confidence: 99%

“…In another study, the effects of implanting AMSCs in autologous platelet‐rich fibrin (PRF) were compared to the effects of using PRF alone to treat chronic DFU healing. They followed this regimen since it is thought to be a more effective and efficient healing method than standard persistent wound care 112 . According to Khalil et al, 112 individuals who received AMSCs in addition to PRF showed better wound healing than those who just received PRF.…”

Section: Stem Cell Therapymentioning

confidence: 99%

“…They followed this regimen since it is thought to be a more effective and efficient healing method than standard persistent wound care 112 . According to Khalil et al, 112 individuals who received AMSCs in addition to PRF showed better wound healing than those who just received PRF. Their findings are in line with previous research suggesting that MSCs release significant amounts of VEGF and HGF and have a higher proportion of transforming growth factor‐3 to TGF‐1, which leads to cell growth, migration, matrix deposition, and enhancement of vascular angiogenesis 112 …”

Section: Stem Cell Therapymentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Hetta,

Elsaghir,

Sijercic

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundDiabetes has evolved into a worldwide public health issue. One of the most serious complications of diabetes is diabetic foot ulcer (DFU), which frequently creates a significant financial strain on patients and lowers their quality of life. Up until now, there has been no curative therapy for DFU, only symptomatic relief or an interruption in the disease's progression. Recent studies have focused attention on mesenchymal stem cells (MSCs), which provide innovative and potential treatment candidates for several illnesses as they can differentiate into various cell types. They are mostly extracted from the placenta, adipose tissue, umbilical cord (UC), and bone marrow (BM). Regardless of their origin, they show comparable features and small deviations. Our goal is to investigate MSCs' therapeutic effects, application obstacles, and patient benefit strategies for DFU therapy.MethodologyA comprehensive search was conducted using specific keywords relating to DFU, MSCs, and connected topics in the databases of Medline, Scopus, Web of Science, and PubMed. The main focus of the selection criteria was on English‐language literature that explored the relationship between DFU, MSCs, and related factors.Results and DiscussionNumerous studies are being conducted and have demonstrated that MSCs can induce re‐epithelialization and angiogenesis, decrease inflammation, contribute to immunological modulation, and subsequently promote DFU healing, making them a promising approach to treating DFU. This review article provides a general snapshot of DFU (including clinical presentation, risk factors and etiopathogenesis, and conventional treatment) and discusses the clinical progress of MSCs in the management of DFU, taking into consideration the side effects and challenges during the application of MSCs and how to overcome these challenges to achieve maximum benefits.ConclusionThe incorporation of MSCs in the management of DFU highlights their potential as a feasible therapeutic strategy. Establishing a comprehensive understanding of the complex relationship between DFU pathophysiology, MSC therapies, and related obstacles is essential for optimizing therapy outcomes and maximizing patient benefits.

show abstract

Using biomaterials to improve mesenchymal stem cell therapies for chronic, nonhealing wounds

Keshavarz,

Olsen,

Almeida

2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Historically, treatment of chronic, nonhealing wounds has focused on managing symptoms using biomaterial‐based wound dressings, which do not adequately address the underlying clinical issue. Mesenchymal stem cells (MSCs) are a promising cell‐based therapy for the treatment of chronic, nonhealing wounds, yet inherent cellular heterogeneity and susceptibility to death during injection limit their clinical use. Recently, researchers have begun to explore the synergistic effects of combined MSC‐biomaterial therapies, where the biomaterial serves as a scaffold to protect the MSCs and provides physiologically relevant physicochemical cues that can direct MSC immunomodulatory behavior. In this review, we highlight recent progress in this field with a focus on the most commonly used biomaterials, classified based on their source, including natural biomaterials, synthetic biomaterials, and the combination of natural and synthetic biomaterials. We also discuss current challenges regarding the clinical translation of these therapies, as well as a perspective on the future outlook of the field.

show abstract

Autologous Adipose-Derived Mesenchymal Stem Cells Embedded in Platelet-Rich Fibrin in Diabetic Foot Ulcers

Cited by 3 publications

References 23 publications

Stem Cell-Based Therapy: A Promising Treatment for Diabetic Foot Ulcer

Stem Cell-Based Therapy: A Promising Treatment for Diabetic Foot Ulcer

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Using biomaterials to improve mesenchymal stem cell therapies for chronic, nonhealing wounds

Contact Info

Product

Resources

About